Is GHK-Cu FDA-approved?
No. GHK-Cu has not been approved as a drug by the FDA. Approval requires full clinical trials and a New Drug Application; GHK-Cu has neither. Being removed from Category 2 in April 2026 changed its compounding status, not its approval status.
Approved vs compoundable vs “research-use” — the distinction that matters
An FDA-approved drug has cleared full clinical trials. A compoundable substance is one a licensed pharmacy may prepare to prescription, even without full approval, if it sits on the 503A Category 1 list. As of April 2026 GHK-Cu was removed from Category 2 because the original nominations were withdrawn — but it was not moved to Category 1, so compounding is still not authorized and it is not covered by FDA enforcement discretion. Products labeled “for research use only” are not authorized for human use. This page does not provide sourcing, dosing, or preparation guidance.
What “not FDA-approved” means here
GHK-Cu has a body of cosmetic and laboratory research for topical skin effects; evidence for injectable systemic use is weaker. Regulatory status changed in April 2026 (see status box).
Will GHK-Cu become legal in 2026?+
Is “research-grade” GHK-Cu the same as a medicine?+
Primary sources: FDA 503A interim list (Apr 2026 update) · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. GHK-Cu is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.